Addex Therapeutics Ltd (FRA:APE)

Market Cap	6.34M -0.9%
Revenue (ttm)	169.46K -71.8%
Net Income	-6.52M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0515
Previous Close	0.0535
Day's Range	0.0515 - 0.0515
52-Week Range	0.0030 - 0.0810
Beta	n/a
RSI	49.88
Earnings Date	Mar 9, 2026

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mG...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: APE

Financial Performance

Financial numbers in CHF